Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
We know that cancer can evade the immune system and that in such instances when drugs are used, especially novels ones, cancer seems especially adept at evading them. So you could say that with a cancer that is smart enough to seed, it is little wonder that it can evade drugs.
So, my question is this. SCIB1 is demonstrating success in several types of outcome measures including ORR and tumour burden. Granted, it must demonstrate a durable response, but why is it successful so far? Reminder the expected outcomes for novel drugs is extremely poor.
Many thanks in advance
RR,
I did like the way in which you have answered RP's question. All though the question itself is a bit tongue in cheek to be sure you have recognised that Immunobody has a value (as Ray asked) and you have translated it into the overall share price. Maybe the values are debatable but quite an interesting method you use, especially over time. Thanks.
Tom,
You seem very emotional. My 8.09 and 8.14 are aimed for TGTD. He is suggesting that it was an RNS when the actual RNS states that it is a Reach no regulatory RNS. Have you actually read the RNS? Because I copied and pasted my 8.14 from the news feed.
Although tissue biopsy is superior too ctDNA liquid biopsy (study of fragments of dead cancer cells) because RNA, DNA, Protein expression can be analysed vs just DNA, it is a one time only. So arguably that puts ctDNA liquid biopsy ahead as it is repeatable and can provide up to date information. My thoughts have been that as Parsortix lacked assays and more importantly a kit to make it usable, it was behind both ctDNA and tissue biopsy. With today's announcement, Angle have put themselves in the game. They have the best of both worlds. Full expression can be analysed and it is repeatable.
The terms and conditions of the Open Offer will be set out in the Circular to be sent to Qualifying Shareholders and (for information only) to Excluded Overseas Shareholders who have notified an address in the United Kingdom for the service of documents in accordance with the Articles. It is expected that the Circular will be dispatched on or around 4 December 2023, and will also be available at this time on the Company's website at www.scancell.co.uk. Further information about the Company and the Capital Raise, including, inter alia, the expected timetable of principal events is set out in Appendix I. Capitalised terms not otherwise defined in the text of this announcement are defined in Appendix IV.
From Thursdays RNS.
I expect a notification on my investment platform so will look out for that. Or visit Scancell website
Not whinging but the one for every forty five shares probably means there will not be many spare shares imo. Unless you all hold millions of shares?!
The last couple of times Scancell raised the share price took off. Also worth pointing out that Scancell have clearly indicated the direction of travel and they appear to have the means to execute its plans. Think the market will be satisfied with this very muchley in the not to distant.
Correct me if I am wrong
Open offer, any qualifying shareholder will be able to apply for one share for every forty five they hold.
Open offer, Scancell will initiate contact Monday 4th December 23
Shares from the placing / subscription of £10.7m are to be submitted AIM at 8am Tuesday 5th December.
So it is possible that submission of the placing and subscription shares (97m) will have an impact on the share price by Tuesday.
Shareholders will still have an option to take part in the open offer @11p until it closes (at a date to be confirmed)
Placing - large investors - funds - institutions?
Subscription - Directors?
Open Offer - Private investors?
Corrections welcome
Agree PB. But in biotech terms not long to wait for very important news and some little fillers along the way.
I remember piling into Synairgen at 10p thinking why isn't everybody doing so. It stayed low for a good while before it took off in a big way. Feels like that might be happening here too? But of course, things can change quickly.
DYOR